DK4110781T3 - 1,3,4-oxadiazolderivatforbindelser som histondeacetylase-6-hæmmer og farmaceutisk sammensætning, der omfatter disse - Google Patents

1,3,4-oxadiazolderivatforbindelser som histondeacetylase-6-hæmmer og farmaceutisk sammensætning, der omfatter disse Download PDF

Info

Publication number
DK4110781T3
DK4110781T3 DK21760609.4T DK21760609T DK4110781T3 DK 4110781 T3 DK4110781 T3 DK 4110781T3 DK 21760609 T DK21760609 T DK 21760609T DK 4110781 T3 DK4110781 T3 DK 4110781T3
Authority
DK
Denmark
Prior art keywords
inhibitors
pharmaceutical compositions
histone deacetylase
derivative compounds
oxadiazole derivative
Prior art date
Application number
DK21760609.4T
Other languages
English (en)
Inventor
Chang Kon Lee
Moo Sung Ko
Seok Hyoun Yun
Seo Young Lee
Hyunjin Michael Kim
Original Assignee
Chong Kun Dang Pharmaceutical Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chong Kun Dang Pharmaceutical Corp filed Critical Chong Kun Dang Pharmaceutical Corp
Application granted granted Critical
Publication of DK4110781T3 publication Critical patent/DK4110781T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
DK21760609.4T 2020-02-25 2021-02-25 1,3,4-oxadiazolderivatforbindelser som histondeacetylase-6-hæmmer og farmaceutisk sammensætning, der omfatter disse DK4110781T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020200023251A KR102537615B1 (ko) 2020-02-25 2020-02-25 히스톤 탈아세틸화효소 6 억제제로서의 1,3,4-옥사다이아졸 유도체 화합물 및 이를 포함하는 약제학적 조성물
PCT/KR2021/002364 WO2021172887A1 (en) 2020-02-25 2021-02-25 1,3,4-oxadiazole derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same

Publications (1)

Publication Number Publication Date
DK4110781T3 true DK4110781T3 (da) 2024-10-14

Family

ID=77490264

Family Applications (1)

Application Number Title Priority Date Filing Date
DK21760609.4T DK4110781T3 (da) 2020-02-25 2021-02-25 1,3,4-oxadiazolderivatforbindelser som histondeacetylase-6-hæmmer og farmaceutisk sammensætning, der omfatter disse

Country Status (21)

Country Link
US (1) US12522601B2 (da)
EP (1) EP4110781B1 (da)
JP (1) JP7428833B2 (da)
KR (1) KR102537615B1 (da)
CN (1) CN115210233B (da)
AU (1) AU2021226297B2 (da)
BR (1) BR112022016761A2 (da)
CA (1) CA3167354A1 (da)
DK (1) DK4110781T3 (da)
ES (1) ES2991287T3 (da)
FI (1) FI4110781T3 (da)
HR (1) HRP20241273T1 (da)
HU (1) HUE068516T2 (da)
MX (1) MX2022010402A (da)
MY (1) MY207739A (da)
NZ (1) NZ791985A (da)
PH (1) PH12022552237A1 (da)
PL (1) PL4110781T3 (da)
PT (1) PT4110781T (da)
TW (1) TWI770841B (da)
WO (1) WO2021172887A1 (da)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018165520A1 (en) 2017-03-10 2018-09-13 Vps-3, Inc. Metalloenzyme inhibitor compounds
AU2020321955A1 (en) 2019-07-30 2022-03-17 Eikonizo Therapapeutics, Inc. HDAC6 inhibitors and uses thereof
KR102537616B1 (ko) 2020-02-25 2023-05-26 주식회사 종근당 히스톤 탈아세틸화 효소 6 억제제로서의 1,3,4-옥사다이아졸 유도체 화합물 및 이를 포함하는 약제학적 조성물
KR102537615B1 (ko) 2020-02-25 2023-05-30 주식회사 종근당 히스톤 탈아세틸화효소 6 억제제로서의 1,3,4-옥사다이아졸 유도체 화합물 및 이를 포함하는 약제학적 조성물
TW202345813A (zh) 2022-04-08 2023-12-01 美商艾科尼佐療法股份有限公司 㗁二唑hdac6抑制劑及其用途
JP2025515466A (ja) * 2022-04-25 2025-05-15 イーライ リリー アンド カンパニー Fgfr2阻害剤化合物

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2427779A1 (en) * 2000-11-10 2002-05-16 Merck Sharp & Dohme Limited Imidazo-triazine derivatives as ligands for gaba receptors
HRP20150642T1 (hr) * 2006-12-22 2015-08-14 Astex Therapeutics Limited BICIKLIÄŚKE HETEROCIKLIÄŚKE TVARI KAO INHIBITORI FGFR-a
CA2690192A1 (en) 2007-06-26 2008-12-31 Gilead Colorado, Inc. Imidazopyridinyl thiazolyl histone deacetylase inhibitors
GB0906470D0 (en) 2009-04-15 2009-05-20 Astex Therapeutics Ltd New compounds
TWI482771B (zh) 2009-05-04 2015-05-01 Du Pont 磺醯胺殺線蟲劑
ES2736200T3 (es) 2009-07-22 2019-12-26 Univ Illinois Inhibidores de HDAC y métodos terapéuticos que utilizan los mismos
EP2480547A4 (en) * 2009-09-23 2013-02-20 Panmira Pharmaceuticals Llc INDOLIZINE INHIBITORS OF 5-LIPOXYGENASE
PH12012501492B1 (en) 2010-01-22 2020-01-24 Acetylon Pharmaceuticals Inc Reverse amide compounds as protein deacetylase inhibitors and methods of use thereof
EA201490228A1 (ru) 2011-07-08 2014-08-29 Новартис Аг Новые производные трифторметилоксадиазола и их применение для лечения заболевания
WO2013041407A1 (en) 2011-09-19 2013-03-28 Cellzome Ag Hydroxamic acids as hdac6 inhibitors
CA2850757A1 (en) 2011-10-03 2013-04-11 The Trustees Of Columbia University In The City Of New York Novel molecules that selectively inhibit histone deacetylase 6 relative to histone deacetylase 1
WO2013066835A2 (en) 2011-10-31 2013-05-10 Glaxosmithkline Llc Compounds and methods
WO2013066833A1 (en) 2011-10-31 2013-05-10 Glaxosmithkline Llc Compounds and methods to inhibit histone deacetylase (hdac) enzymes
WO2013066838A1 (en) 2011-10-31 2013-05-10 Glaxosmithkline Llc Compounds and methods
WO2013066839A2 (en) 2011-10-31 2013-05-10 Glaxosmithkline Llc Compounds and methods
BR112014012815A8 (pt) 2011-11-28 2017-06-20 Novartis Ag derivados de trifluormetil-oxadiazol e uso dos mesmos no tratamento de doença
JP6233812B2 (ja) 2012-03-07 2017-11-22 エイチ リー モフィット キャンサー センター アンド リサーチ インスティテュート インコーポレイテッド 選択的ヒストンデアセチラーゼ6阻害剤
US9511178B2 (en) * 2012-07-09 2016-12-06 Medtronic, Inc. Reducing centrifugal pump bearing wear through dynamic magnetic coupling
JP2018503830A (ja) 2015-02-02 2018-02-08 ツー ポア ガイズ インコーポレイテッド バイオマーカー検出のための不安定なリンカー
PL3328843T3 (pl) 2015-07-27 2023-02-27 Chong Kun Dang Pharmaceutical Corp. Związki będące pochodnymi 1,3,4 oksadiazolosulfonamidów jako inhibitor deacetylazy histonowej 6, oraz kompozycja farmaceutyczna je zawierająca
CN108026056B (zh) 2015-07-27 2021-08-03 株式会社钟根堂 作为组蛋白脱乙酰酶6抑制剂的1,3,4-噁二唑酰胺衍生物化合物及其药物组合物
RU2695227C9 (ru) 2015-07-27 2020-03-04 Чонг Кун Данг Фармасьютикал Корп. Производные 1,3,4-оксадиазолсульфамида в качестве ингибитора гистондеацетилазы 6 и содержащая их фармацевтическая композиция
JP6491393B2 (ja) 2015-08-04 2019-03-27 チョン クン ダン ファーマシューティカル コーポレーション ヒストン脱アセチル化酵素6阻害剤としての1,3,4−オキサジアゾール誘導体化合物及びこれを含有する薬剤学的組成物
US10723705B2 (en) 2015-08-14 2020-07-28 Incyte Corporation Heterocyclic compounds and uses thereof
WO2017222950A1 (en) * 2016-06-23 2017-12-28 Merck Sharp & Dohme Corp. 3-heterocyclyl substituted 5-trifluoromethyl oxadiazoles as histone deacetylase 6 (hdac6) inhibitors
WO2017222951A1 (en) 2016-06-23 2017-12-28 Merck Sharp & Dohme Corp. 3-aryl and heteroaryl substituted 5-trifluoromethyl oxadiazoles as histone deacetylase 6 (hdac6) inhibitors
SG11202005254RA (en) 2017-12-05 2020-07-29 Oryzon Genomics Sa 1,2,4-oxadiazole derivatives as histone deacetylase 6 inhibitors
MX2022007376A (es) 2019-12-20 2022-09-02 Tenaya Therapeutics Inc Fluoroalqull-oxadiazoles y sus usos.
KR102537615B1 (ko) 2020-02-25 2023-05-30 주식회사 종근당 히스톤 탈아세틸화효소 6 억제제로서의 1,3,4-옥사다이아졸 유도체 화합물 및 이를 포함하는 약제학적 조성물
KR102537616B1 (ko) * 2020-02-25 2023-05-26 주식회사 종근당 히스톤 탈아세틸화 효소 6 억제제로서의 1,3,4-옥사다이아졸 유도체 화합물 및 이를 포함하는 약제학적 조성물

Also Published As

Publication number Publication date
WO2021172887A1 (en) 2021-09-02
PT4110781T (pt) 2024-09-25
US12522601B2 (en) 2026-01-13
JP7428833B2 (ja) 2024-02-06
JP2023516102A (ja) 2023-04-17
CN115210233A (zh) 2022-10-18
HRP20241273T1 (hr) 2024-12-06
ES2991287T3 (es) 2024-12-03
KR102537615B1 (ko) 2023-05-30
MX2022010402A (es) 2022-09-07
HUE068516T2 (hu) 2024-12-28
MY207739A (en) 2025-03-15
BR112022016761A2 (pt) 2022-10-18
AU2021226297A1 (en) 2022-09-29
US20230271955A1 (en) 2023-08-31
CN115210233B (zh) 2025-02-14
NZ791985A (en) 2026-03-27
TW202146409A (zh) 2021-12-16
PH12022552237A1 (en) 2024-02-12
EP4110781A1 (en) 2023-01-04
AU2021226297B2 (en) 2023-12-21
TWI770841B (zh) 2022-07-11
EP4110781A4 (en) 2023-08-09
FI4110781T3 (fi) 2024-10-23
EP4110781B1 (en) 2024-07-31
KR20210108555A (ko) 2021-09-03
CA3167354A1 (en) 2021-09-02
PL4110781T3 (pl) 2025-01-20

Similar Documents

Publication Publication Date Title
DK4110781T3 (da) 1,3,4-oxadiazolderivatforbindelser som histondeacetylase-6-hæmmer og farmaceutisk sammensætning, der omfatter disse
DK4110780T3 (da) 1,3,4-oxadiazolderivatforbindelser som histondeacetylase-6-hæmmer og farmaceutisk sammensætning, der omfatter disse
DK3956324T3 (da) 1,3,4-oxadiazol-derivater som histondeacetylase-inhibitorer
DK3976604T3 (da) 1,3,4-oxadiazol-derivatforbindelser som histondeacetylase 6-hæmmer og den farmaceutiske sammensætning, der omfatter den samme
DK3330259T3 (da) 1,3,4-oxadiazolamidderivativ-forbindelse som histondeacetylase-6-inhibitor og farmaceutisk sammensætning indeholdende denne
DK3328843T3 (da) 1,3,4-oxadiazolsulfonamidderivat-forbindelser som histon- deacetylase-6-inhibitor, og den farmaceutske sammensætning
DK3328844T3 (da) 1,3,4-oxadiazolsulfamidderivater som histondeacetylase-6-inhibitor og farmaceutisk sammensætning omfattende samme
DK3911647T3 (da) Isoxazol-forbindelse som FXR-agonist og farmaceutiske sammensætninger, der omfatter en sådan
DK3442973T3 (da) Hidtil ukendte forbindelser som autotaxinhæmmere og farmaceutiske sammensætninger omfattende samme
HUE061967T2 (hu) Hiszton deacetiláz-6 inhibitor oxadiazol-amin származékok és az azokat tartalmazó gyógyászati készítmény
PT3331864T (pt) Compostos derivados de 1,3,4-oxadiazol como inibidor de histona desacetilase 6 e a composição farmacêutica compreendendo os mesmos
PH12020550698A1 (en) 1,2,4-oxadiazole derivatives as histone deacetylase 6 inhibitors
NO20044444L (no) Benzamidderivater nyttige som histondeacetylase inhibitorer
EP3976602A4 (en) 1,3,4-OXADIAZOLE HOMOPHTHALIMIDE DERIVATIVE COMPOUNDS AS HISTONE DEACETYLASE-6 INHIBITOR AND PHARMACEUTICAL COMPOSITION THEREOF
DK3297992T3 (da) Heterocykliske alkylderivatforbindelser som selektive histondeacetylase-inhibitorer og farmaceutiske sammensætninger omfattende samme
EP4208461A4 (en) NOVEL COMPOUNDS AS HISTONE DEACETYLASE-6 INHIBITORS AND PHARMACEUTICAL COMPOSITIONS THEREOF
BR112015023434A8 (pt) compostos inibidores de histona deacetilase, seu uso e composição farmacêutica que os compreende
EP3883572A4 (en) PHARMACEUTICAL COMPOSITION WITH HISTONE DEACETYLASE-6 INHIBITORS
IL318056A (en) 1,3,4-Oxadiazole Derivatives as Selective Histone Deacetylase 6 Inhibitors
EP4288419A4 (en) 1,3,4-OXADIAZOLE THIOCARBONYL COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND PHARMACEUTICAL COMPOSITION COMPRISING THEM
DK4214210T3 (da) Forbindelser og sammensætninger som sppl2a-inhibitorer
CL2009001150A1 (es) Compuestos derivados de n-(2-amino-fenil)-acrilamidas, inhibidor de la histona-desacetilasa (hdac); procedimiento de preparacion; composicion faramceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer.
IL307471A (en) URAT1 inhibitor, pharmaceutical preparations and their uses
IL319658A (en) Sulfoximine compounds as histone deacetylase 6 inhibitors, and a pharmaceutical composition comprising the same
EP4494640A4 (en) Novel heterocyclic inhibitor for histone deacetylase, and pharmaceutical composition comprising same